Skip to content
AnalystLens

JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 13, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 13, 2026
Period End
October 13, 2026
Security
JNJ
In the record · 2016–202610-K1110-Q338-K134

JNJ filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Jan ’16Jan ’16
  2. Restructuring8-K · Apr ’18Apr ’18
  3. Leadership change8-K · Oct ’21Oct ’21
  4. Leadership change8-K · Sep ’25Sep ’25

01—Abstract

Summary

Summary of the 8-K filed October 13, 2026. Cited figures are marked; the original filing is the authoritative source.

Johnson & Johnson reported third-quarter 2026 results (quarter ended September 27, 2026) with reported sales of $25.4 billiona, up 5.9% year over year (6.0% operational, 6.1% adjusted operational).

Growth was led by the U.S. (+9.1%) and Innovative Medicine (+7.7% reported, +8.0% adjusted operational), driven by TREMFYA, oncology franchises (DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE) and neuroscience (SPRAVATO, CAPLYTA), partially offset by the STELARA erosion (roughly 690 basis points of drag). MedTech grew 2.5%, with electrophysiology, Shockwave and contact lenses leading. GAAP profitability was sharply lower: net earnings fell 95.9% to $210 millionb and diluted EPS was $0.09, versus $2.12 a year ago.

The decline reflects a one-time special charge of about $5.5 billionc in litigation-related pre-tax adjustments tied to the proposed ovarian talc litigation resolution, plus IPR&D impairments of $339 million, Orthopaedics separation costs, and the Firefly Bio acquisition and Sail Biomedicines collaboration. Excluding these special items and intangible amortization, adjusted EPS was $2.59, down 7.5% from $2.80. Free cash flow was estimated at about $15.1 billion year to date.

Management raised full-year 2026 guidance: estimated reported sales of $101.0d-$101.4 billion (7.4% growth at midpoint, up from 7.3%) and adjusted EPS of $11.05-$11.15 (midpoint $11.10, up $0.06). Investors should weigh the strong top-line momentum against the large talc-related charge, the continued STELARA decline and the still-pending cash timing of the talc settlement, which the release does not fully quantify in this filing.

02—Key points

Key Highlights

  1. Q3 2026 reported sales rose 5.9% to $25.4 billion; U.S. sales grew 9.1% while International grew 1.5% (1.8% operational).
  2. GAAP diluted EPS fell to $0.09 from $2.12, driven by about $5.5 billion in pre-tax litigation charges tied to the proposed ovarian talc resolution.
  3. Adjusted diluted EPS was $2.59, down 7.5%, and adjusted operational growth reached 6.1%, with Innovative Medicine up 8.0%.
  4. Full-year 2026 guidance was raised: reported sales of $101.0-$101.4 billion (7.4% midpoint growth) and adjusted EPS of $11.05-$11.15, up $0.06 at the midpoint.
  5. TREMFYA sales nearly doubled-plus to $2.4 billion (+68.3%), while STELARA fell 54.4% to $716 million as biosimilar erosion continued.
  6. Regulatory milestones included FDA market authorization for the OTTAVA robotic surgical system, FDA approval of IMAAVY for warm autoimmune hemolytic anemia, and priority review for RYBREVANT FASPRO in head and neck cancer.
  7. R&D expense rose 26.7% to $4.65 billion, and IPR&D impairments of $339 million were recorded, reflecting continued investment in pipeline and M&A.

03—Questions

Frequently Asked Questions

  1. Why did GAAP earnings fall so sharply in the third quarter?

    GAAP net earnings dropped 95.9% to $210 million mainly because of a one-time special charge of roughly $5.5 billion in pre-tax litigation-related expense for the proposed resolution of ovarian talc litigation. Additional items included $339 million of IPR&D impairments, $369 million of Orthopaedics separation costs and acquisition-related charges. Adjusted EPS, which excludes these items and intangible amortization, was $2.59.

  2. Is the guidance increase meaningful for investors?

    The raise is modest. Reported sales guidance moved up about $100 million at both ends to $101.0-$101.4 billion, and adjusted EPS guidance rose $0.06 to a midpoint of $11.10, or 2.9% growth. Adjusted operational sales growth guidance was lifted to 6.4%-6.8%, suggesting underlying momentum is slightly better than previously expected.

  3. How significant is the STELARA decline for the growth outlook?

    STELARA sales fell 54.4% to $716 million and represented an approximate 690 basis point drag on Innovative Medicine growth in the quarter. Growth from TREMFYA, oncology and neuroscience products offset this decline, but continued erosion remains a key headwind to watch as biosimilar competition persists.

  4. What does the talc resolution mean for the company's cash position?

    The filing records a large non-cash-to-date accounting charge for the proposed ovarian talc resolution, but this 8-K release does not detail the payment timing or total settlement cash outlay. Investors should review the forthcoming 10-Q and litigation disclosures for payment schedules, insurance recoveries and effects on free cash flow, which was estimated at about $15.1 billion year to date.

04—Continue

← View all 8-K filings